Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke

William Tobin, J. A. Kinsella, G. F. Kavanagh, J. S. O'Donnell, R. A. McGrath, D. R. Collins, T. Coughlan, D. O'Neill, B. Egan, S. Tierney, T. M. Feeley, R. P. Murphy, Dominick J H McCabe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The impact of changing antiplatelet therapy on thrombin generation potential in patients with ischaemic cerebrovascular disease (CVD) is unclear. We assessed patients within 4 weeks of TIA or ischaemic stroke (baseline), and then 14 days (14d) and >90 days (90d) after altering antiplatelet therapy. Thrombin generation was assessed in platelet poor plasma. Ninety-one patients were recruited. Twenty-four were initially assessed on no antiplatelet therapy, and then after 14d (N = 23) and 90d (N = 8) on aspirin monotherapy; 52 were assessed on aspirin monotherapy, and after 14 and 90 days on aspirin and dipyridamole combination therapy; 21 patients were assessed on aspirin and after 14 days (N = 21) and 90 days (N = 19) on clopidogrel. Peak thrombin generation and endogenous thrombin potential were reduced at 14 and 90 days (p ≤ 0.04) in the overall cohort. We assessed the impact of individual antiplatelet regimens on thrombin generation parameters to investigate the cause of this effect. Lag time and time-to-peak thrombin generation were unchanged at 14 days, but reduced 90 days after commencing aspirin (p ≤ 0.009). Lag time, peak thrombin generation and endogenous thrombin potential were reduced at both 14 and 90 days after adding dipyridamole to aspirin (p ≤ 0.01). Lag time was reduced 14 days after changing from aspirin to clopidogrel (p = 0.045), but this effect was not maintained at 90 days (p = 0.2). This pilot study did not show any consistent effects of commencing aspirin, or of changing from aspirin to clopidogrel on thrombin generation potential during follow-up. The addition of dipyridamole to aspirin led to a persistent reduction in peak and total thrombin generation ex vivo, and illustrates the diverse, potentially beneficial, newly recognised 'anti-coagulant' effects of dipyridamole in ischaemic CVD.

Original languageEnglish (US)
Pages (from-to)590-596
Number of pages7
JournalJournal of Neurology
Volume260
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Thrombin
Aspirin
Stroke
clopidogrel
Dipyridamole
Therapeutics
Cerebrovascular Disorders
Thrombin Time
Coagulants
Blood Platelets

Keywords

  • Antiplatelet responsiveness
  • Aspirin
  • Clopidogrel
  • Dipyridamole
  • Stroke
  • Thrombin generation potential
  • TIA

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. / Tobin, William; Kinsella, J. A.; Kavanagh, G. F.; O'Donnell, J. S.; McGrath, R. A.; Collins, D. R.; Coughlan, T.; O'Neill, D.; Egan, B.; Tierney, S.; Feeley, T. M.; Murphy, R. P.; McCabe, Dominick J H.

In: Journal of Neurology, Vol. 260, No. 2, 02.2013, p. 590-596.

Research output: Contribution to journalArticle

Tobin, W, Kinsella, JA, Kavanagh, GF, O'Donnell, JS, McGrath, RA, Collins, DR, Coughlan, T, O'Neill, D, Egan, B, Tierney, S, Feeley, TM, Murphy, RP & McCabe, DJH 2013, 'Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke', Journal of Neurology, vol. 260, no. 2, pp. 590-596. https://doi.org/10.1007/s00415-012-6684-2
Tobin, William ; Kinsella, J. A. ; Kavanagh, G. F. ; O'Donnell, J. S. ; McGrath, R. A. ; Collins, D. R. ; Coughlan, T. ; O'Neill, D. ; Egan, B. ; Tierney, S. ; Feeley, T. M. ; Murphy, R. P. ; McCabe, Dominick J H. / Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. In: Journal of Neurology. 2013 ; Vol. 260, No. 2. pp. 590-596.
@article{b6609f2f8ee74cb094a6e28bb5819d2a,
title = "Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke",
abstract = "The impact of changing antiplatelet therapy on thrombin generation potential in patients with ischaemic cerebrovascular disease (CVD) is unclear. We assessed patients within 4 weeks of TIA or ischaemic stroke (baseline), and then 14 days (14d) and >90 days (90d) after altering antiplatelet therapy. Thrombin generation was assessed in platelet poor plasma. Ninety-one patients were recruited. Twenty-four were initially assessed on no antiplatelet therapy, and then after 14d (N = 23) and 90d (N = 8) on aspirin monotherapy; 52 were assessed on aspirin monotherapy, and after 14 and 90 days on aspirin and dipyridamole combination therapy; 21 patients were assessed on aspirin and after 14 days (N = 21) and 90 days (N = 19) on clopidogrel. Peak thrombin generation and endogenous thrombin potential were reduced at 14 and 90 days (p ≤ 0.04) in the overall cohort. We assessed the impact of individual antiplatelet regimens on thrombin generation parameters to investigate the cause of this effect. Lag time and time-to-peak thrombin generation were unchanged at 14 days, but reduced 90 days after commencing aspirin (p ≤ 0.009). Lag time, peak thrombin generation and endogenous thrombin potential were reduced at both 14 and 90 days after adding dipyridamole to aspirin (p ≤ 0.01). Lag time was reduced 14 days after changing from aspirin to clopidogrel (p = 0.045), but this effect was not maintained at 90 days (p = 0.2). This pilot study did not show any consistent effects of commencing aspirin, or of changing from aspirin to clopidogrel on thrombin generation potential during follow-up. The addition of dipyridamole to aspirin led to a persistent reduction in peak and total thrombin generation ex vivo, and illustrates the diverse, potentially beneficial, newly recognised 'anti-coagulant' effects of dipyridamole in ischaemic CVD.",
keywords = "Antiplatelet responsiveness, Aspirin, Clopidogrel, Dipyridamole, Stroke, Thrombin generation potential, TIA",
author = "William Tobin and Kinsella, {J. A.} and Kavanagh, {G. F.} and O'Donnell, {J. S.} and McGrath, {R. A.} and Collins, {D. R.} and T. Coughlan and D. O'Neill and B. Egan and S. Tierney and Feeley, {T. M.} and Murphy, {R. P.} and McCabe, {Dominick J H}",
year = "2013",
month = "2",
doi = "10.1007/s00415-012-6684-2",
language = "English (US)",
volume = "260",
pages = "590--596",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

TY - JOUR

T1 - Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke

AU - Tobin, William

AU - Kinsella, J. A.

AU - Kavanagh, G. F.

AU - O'Donnell, J. S.

AU - McGrath, R. A.

AU - Collins, D. R.

AU - Coughlan, T.

AU - O'Neill, D.

AU - Egan, B.

AU - Tierney, S.

AU - Feeley, T. M.

AU - Murphy, R. P.

AU - McCabe, Dominick J H

PY - 2013/2

Y1 - 2013/2

N2 - The impact of changing antiplatelet therapy on thrombin generation potential in patients with ischaemic cerebrovascular disease (CVD) is unclear. We assessed patients within 4 weeks of TIA or ischaemic stroke (baseline), and then 14 days (14d) and >90 days (90d) after altering antiplatelet therapy. Thrombin generation was assessed in platelet poor plasma. Ninety-one patients were recruited. Twenty-four were initially assessed on no antiplatelet therapy, and then after 14d (N = 23) and 90d (N = 8) on aspirin monotherapy; 52 were assessed on aspirin monotherapy, and after 14 and 90 days on aspirin and dipyridamole combination therapy; 21 patients were assessed on aspirin and after 14 days (N = 21) and 90 days (N = 19) on clopidogrel. Peak thrombin generation and endogenous thrombin potential were reduced at 14 and 90 days (p ≤ 0.04) in the overall cohort. We assessed the impact of individual antiplatelet regimens on thrombin generation parameters to investigate the cause of this effect. Lag time and time-to-peak thrombin generation were unchanged at 14 days, but reduced 90 days after commencing aspirin (p ≤ 0.009). Lag time, peak thrombin generation and endogenous thrombin potential were reduced at both 14 and 90 days after adding dipyridamole to aspirin (p ≤ 0.01). Lag time was reduced 14 days after changing from aspirin to clopidogrel (p = 0.045), but this effect was not maintained at 90 days (p = 0.2). This pilot study did not show any consistent effects of commencing aspirin, or of changing from aspirin to clopidogrel on thrombin generation potential during follow-up. The addition of dipyridamole to aspirin led to a persistent reduction in peak and total thrombin generation ex vivo, and illustrates the diverse, potentially beneficial, newly recognised 'anti-coagulant' effects of dipyridamole in ischaemic CVD.

AB - The impact of changing antiplatelet therapy on thrombin generation potential in patients with ischaemic cerebrovascular disease (CVD) is unclear. We assessed patients within 4 weeks of TIA or ischaemic stroke (baseline), and then 14 days (14d) and >90 days (90d) after altering antiplatelet therapy. Thrombin generation was assessed in platelet poor plasma. Ninety-one patients were recruited. Twenty-four were initially assessed on no antiplatelet therapy, and then after 14d (N = 23) and 90d (N = 8) on aspirin monotherapy; 52 were assessed on aspirin monotherapy, and after 14 and 90 days on aspirin and dipyridamole combination therapy; 21 patients were assessed on aspirin and after 14 days (N = 21) and 90 days (N = 19) on clopidogrel. Peak thrombin generation and endogenous thrombin potential were reduced at 14 and 90 days (p ≤ 0.04) in the overall cohort. We assessed the impact of individual antiplatelet regimens on thrombin generation parameters to investigate the cause of this effect. Lag time and time-to-peak thrombin generation were unchanged at 14 days, but reduced 90 days after commencing aspirin (p ≤ 0.009). Lag time, peak thrombin generation and endogenous thrombin potential were reduced at both 14 and 90 days after adding dipyridamole to aspirin (p ≤ 0.01). Lag time was reduced 14 days after changing from aspirin to clopidogrel (p = 0.045), but this effect was not maintained at 90 days (p = 0.2). This pilot study did not show any consistent effects of commencing aspirin, or of changing from aspirin to clopidogrel on thrombin generation potential during follow-up. The addition of dipyridamole to aspirin led to a persistent reduction in peak and total thrombin generation ex vivo, and illustrates the diverse, potentially beneficial, newly recognised 'anti-coagulant' effects of dipyridamole in ischaemic CVD.

KW - Antiplatelet responsiveness

KW - Aspirin

KW - Clopidogrel

KW - Dipyridamole

KW - Stroke

KW - Thrombin generation potential

KW - TIA

UR - http://www.scopus.com/inward/record.url?scp=84878830669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878830669&partnerID=8YFLogxK

U2 - 10.1007/s00415-012-6684-2

DO - 10.1007/s00415-012-6684-2

M3 - Article

VL - 260

SP - 590

EP - 596

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 2

ER -